Ning Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ning Liu has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Jian-Qiang Yu
College of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan 750004, China
5 shared publications - Yue Liu
College of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan 750004, China
4 shared publications Lin Ma
3 shared publications- Chun-Hao Zhu
College of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan 750004, China
2 shared publications Dongmei Hai
2 shared publications- Lin Ma
College of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan 750004, China
2 shared publications
Latest Publications
- Open Access
Cistanche deserticola: A Homology-of-Medicine-and-Food Herb with Intestinal-Moistening and Laxative Effects
Cistanche deserticola is a perennial parasitic herb of the Orobanchaceae family and a traditional Chinese medicinal material included in the homology-of-medicine-and-food category. It has traditionally been used to nourish the kidney and essence and to relieve constipation. Recent studies have investigated its potential effects on intestinal motility, gut microbiota, and fecal water regulation. This review summarizes the reported chemical constituents of C. deserticola, including phenylethanoid glycosides, polysaccharides, flavonoids, and sugar alcohols, and examines the available evidence regarding their potential contributions to laxative effects. Possible mechanisms involving intestinal motility, neurotransmitter-related signaling, gut microbiota and microbial metabolites, and aquaporin expression are discussed. Evidence is considered hierarchically: findings from identified C. deserticola preparations are distinguished from indirect findings involving other Cistanche species, isolated compounds, or multi-component herbal formulations, while proposed causal pathways are treated as hypotheses unless directly tested. The evidence base is predominantly preclinical, and human studies are limited; the specific contributions of individual constituents, the causal relationships underlying the proposed mechanisms, and the long-term safety of different preparations remain insufficiently established. This review also discusses challenges in raw-material standardization, evidence-based quality control, and functional food development, highlighting the need for further mechanistic, toxicological, and clinical studies to support the rational development of C. deserticola-based products.
Open AccessCistanche deserticola: A Homology-of-Medicine-and-Food Herb with Intestinal-Moistening and Laxative Effects
Cistanche deserticola is a perennial parasitic herb of the Orobanchaceae family and a traditional Chinese medicinal material included in the homology-of-medicine-and-food category. It has traditionally been used to nourish the kidney and essence and to relieve constipation. Recent studies have investigated its potential effects on intestinal motility, gut microbiota, and fecal water regulation. This review summarizes the reported chemical constituents of C. deserticola, including phenylethanoid glycosides, polysaccharides, flavonoids, and sugar alcohols, and examines the available evidence regarding their potential contributions to laxative effects. Possible mechanisms involving intestinal motility, neurotransmitter-related signaling, gut microbiota and microbial metabolites, and aquaporin expression are discussed. Evidence is considered hierarchically: findings from identified C. deserticola preparations are distinguished from indirect findings involving other Cistanche species, isolated compounds, or multi-component herbal formulations, while proposed causal pathways are treated as hypotheses unless directly tested. The evidence base is predominantly preclinical, and human studies are limited; the specific contributions of individual constituents, the causal relationships underlying the proposed mechanisms, and the long-term safety of different preparations remain insufficiently established. This review also discusses challenges in raw-material standardization, evidence-based quality control, and functional food development, highlighting the need for further mechanistic, toxicological, and clinical studies to support the rational development of C. deserticola-based products.
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 468
Study on the Analgesic Mechanism of Aloperine in Mice with Neuropathic Pain Based on the p38MAPK/FKN/CX3CR1 Pathway
A lesion or disease of the somatosensory nervous system causes neuropathic pain (NP). Previous experiments have demonstrated that aloperine (ALO) exhibits antiallodynic effects on neuropathic pain in mice; however, the mechanism underlying its analgesic action remains unclear. This study investigated the analgesic mechanism of ALO on neuropathic pain in mice using a chronic constriction injury (CCI) model. Experiments were conducted using the ALO and p38MAPK inhibitor SB 203580. In vivo experiments demonstrated that ALO played an analgesic role by inhibiting p38MAPK phosphorylation, and it improved mechanical allodynia, cold allodynia, and hot hyperalgesia in CCI mice, as well as having a protective effect on injured sciatic nerves. The combined administration of a subthreshold dose of ALO (20 mg/kg) with the p38MAPK inhibitor SB203580 (20 mg/kg) produced significant analgesic effects, suggesting that ALO likely shares a common target with SB203580, namely p38MAPK. Fluorescence double staining indicated that the antiallodynic effect of ALO may be related to its inhibition of the p38MAPK/FKN/CX3CR1 pathway in the spinal cord, and it may play a role in regulating the expression of p38MAPK in microglial cells. In vitro studies have shown that ALO can reduce the activation of BV2 cells, inhibit p38MAPK phosphorylation in microglia, and play a role in regulating the p38MAPK protein. In conclusion, our results suggest that the analgesic mechanism of aloperine is associated with its inhibition of the FKN/CX3CR1 pathway, which is regulated by p38MAPK phosphorylation in spinal microglia. This study provides new potential targets for the analgesic mechanism of aloperine. Graphical Abstract
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 468
Study on the Analgesic Mechanism of Aloperine in Mice with Neuropathic Pain Based on the p38MAPK/FKN/CX3CR1 Pathway
A lesion or disease of the somatosensory nervous system causes neuropathic pain (NP). Previous experiments have demonstrated that aloperine (ALO) exhibits antiallodynic effects on neuropathic pain in mice; however, the mechanism underlying its analgesic action remains unclear. This study investigated the analgesic mechanism of ALO on neuropathic pain in mice using a chronic constriction injury (CCI) model. Experiments were conducted using the ALO and p38MAPK inhibitor SB 203580. In vivo experiments demonstrated that ALO played an analgesic role by inhibiting p38MAPK phosphorylation, and it improved mechanical allodynia, cold allodynia, and hot hyperalgesia in CCI mice, as well as having a protective effect on injured sciatic nerves. The combined administration of a subthreshold dose of ALO (20 mg/kg) with the p38MAPK inhibitor SB203580 (20 mg/kg) produced significant analgesic effects, suggesting that ALO likely shares a common target with SB203580, namely p38MAPK. Fluorescence double staining indicated that the antiallodynic effect of ALO may be related to its inhibition of the p38MAPK/FKN/CX3CR1 pathway in the spinal cord, and it may play a role in regulating the expression of p38MAPK in microglial cells. In vitro studies have shown that ALO can reduce the activation of BV2 cells, inhibit p38MAPK phosphorylation in microglia, and play a role in regulating the p38MAPK protein. In conclusion, our results suggest that the analgesic mechanism of aloperine is associated with its inhibition of the FKN/CX3CR1 pathway, which is regulated by p38MAPK phosphorylation in spinal microglia. This study provides new potential targets for the analgesic mechanism of aloperine. Graphical Abstract
- 29 May 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 351, 120072
Cannabidiol ameliorates seizures and neuronal damage in ferric chloride-induced posttraumatic epilepsy by targeting TRPV1 channel
- 29 May 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 351, 120072
Cannabidiol ameliorates seizures and neuronal damage in ferric chloride-induced posttraumatic epilepsy by targeting TRPV1 channel
- Open Access
- 22 May 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (6) , 749
Mechanistic Insights into the Mechanism of Allosteric Inhibition of Ubiquitin-Specific Protease 7 (USP7)
Ubiquitin-specific protease 7 (USP7), a deubiquitinase enzyme responsible for removing ubiquitin (Ub) from target proteins, plays a crucial role in oncogenic pathways and has been implicated in various human diseases. X-ray crystallography has revealed distinct conformations of USP7, including apo (ligand-free), allosteric inhibitor-, and Ub-bound states. However, the dynamic mechanisms underlying the allosteric inhibition of USP7 remain unclear. This study investigates the effect of allosteric inhibitor binding on the dynamics of USP7 through multiple replica molecular dynamics simulations. Our results demonstrate that Ub binding stabilizes the USP7 conformation, while allosteric inhibitor binding increases flexibility and variability in the fingers and palm domains of USP7. Furthermore, our analysis of USP7 local regions reveals that allosteric inhibitor binding not only restrains the dynamics of the C-terminal Ub binding site, thereby impeding the accessibility of Ub to USP7, but also disrupts the proper alignment of the catalytic triad (Cys223-His464-Asp481) in USP7. Additionally, community network analysis indicates that intra-domain communications within the fingers domain in USP7 are significantly enhanced upon allosteric inhibitor binding. This study reveals that the binding of an allosteric inhibitor induces a dynamic shift in enzyme’s conformational equilibrium, effectively disrupting its catalytic activity through allosteric modulation.
- 22 May 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (6) , 749
Open AccessMechanistic Insights into the Mechanism of Allosteric Inhibition of Ubiquitin-Specific Protease 7 (USP7)
Ubiquitin-specific protease 7 (USP7), a deubiquitinase enzyme responsible for removing ubiquitin (Ub) from target proteins, plays a crucial role in oncogenic pathways and has been implicated in various human diseases. X-ray crystallography has revealed distinct conformations of USP7, including apo (ligand-free), allosteric inhibitor-, and Ub-bound states. However, the dynamic mechanisms underlying the allosteric inhibition of USP7 remain unclear. This study investigates the effect of allosteric inhibitor binding on the dynamics of USP7 through multiple replica molecular dynamics simulations. Our results demonstrate that Ub binding stabilizes the USP7 conformation, while allosteric inhibitor binding increases flexibility and variability in the fingers and palm domains of USP7. Furthermore, our analysis of USP7 local regions reveals that allosteric inhibitor binding not only restrains the dynamics of the C-terminal Ub binding site, thereby impeding the accessibility of Ub to USP7, but also disrupts the proper alignment of the catalytic triad (Cys223-His464-Asp481) in USP7. Additionally, community network analysis indicates that intra-domain communications within the fingers domain in USP7 are significantly enhanced upon allosteric inhibitor binding. This study reveals that the binding of an allosteric inhibitor induces a dynamic shift in enzyme’s conformational equilibrium, effectively disrupting its catalytic activity through allosteric modulation.
- Open Access
- 6 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Novel histone deacetylase-5 inhibitor T2943 exerts an anti-depressive effect in mice by enhancing GRID1 expression
Histone deacetylase-5 (HDAC5) is implicated in the pathogenesis of depression and the mechanistic pathways underlying the effects of antidepressant medications. We previously identified a novel HDAC5 inhibitor, T2943, with antidepressant properties that promote histone 3 lysine-14 acetylation (H3K14ac) by inhibiting HDAC5 activity. In this study, we identify the core genes promoting transcription and expression following T2943-mediated upregulation of H3K14ac, highlighting Grid1 (GluD1) as a central gene. We used cleavage under targets and tagmentation (CUT&Tag), gene set enrichment analysis, and behavioral tests after GRID1 (glutamate receptor delta-1 subunit) knockdown. Gene ontology and pathway enrichment analysis via CUT&Tag suggested the following mechanism for the antidepressant action of T2943: T2943 inhibits HDAC5 activity to promote H3K14 acetylation. This modification loosens the chromatin structure, allowing transcription factors to bind to the Grid1 promoter region and enhance its transcription and expression. Upregulated GRID1 mediates signal transmission in neural pathways, restores the regenerative ability of hippocampal nerve cells, promotes nerve growth and synaptic formation, increases synapse numbers, and enhances synaptic function. Our findings highlight the therapeutic potential of targeting HDAC5 in depression and clarify the antidepressant mechanism of T2943.
- 6 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Open AccessNovel histone deacetylase-5 inhibitor T2943 exerts an anti-depressive effect in mice by enhancing GRID1 expression
Histone deacetylase-5 (HDAC5) is implicated in the pathogenesis of depression and the mechanistic pathways underlying the effects of antidepressant medications. We previously identified a novel HDAC5 inhibitor, T2943, with antidepressant properties that promote histone 3 lysine-14 acetylation (H3K14ac) by inhibiting HDAC5 activity. In this study, we identify the core genes promoting transcription and expression following T2943-mediated upregulation of H3K14ac, highlighting Grid1 (GluD1) as a central gene. We used cleavage under targets and tagmentation (CUT&Tag), gene set enrichment analysis, and behavioral tests after GRID1 (glutamate receptor delta-1 subunit) knockdown. Gene ontology and pathway enrichment analysis via CUT&Tag suggested the following mechanism for the antidepressant action of T2943: T2943 inhibits HDAC5 activity to promote H3K14 acetylation. This modification loosens the chromatin structure, allowing transcription factors to bind to the Grid1 promoter region and enhance its transcription and expression. Upregulated GRID1 mediates signal transmission in neural pathways, restores the regenerative ability of hippocampal nerve cells, promotes nerve growth and synaptic formation, increases synapse numbers, and enhances synaptic function. Our findings highlight the therapeutic potential of targeting HDAC5 in depression and clarify the antidepressant mechanism of T2943.
- 4 October 2024
- Published by Elsevier in Neuroscience
- Vol. 560, 406-421
Negative allosteric modulator of Group Ⅰ mGluRs: Recent advances and therapeutic perspective for neuropathic pain
- 4 October 2024
- Published by Elsevier in Neuroscience
- Vol. 560, 406-421
Negative allosteric modulator of Group Ⅰ mGluRs: Recent advances and therapeutic perspective for neuropathic pain